Artificial Intelligence (AI) Assisted Discovery of Novel FXR Agonists for NASH Treatment
Abstract
Background: Non-alcoholic steatohepatitis (NASH) is a chronic metabolic disease characterized by lipid accumulation, inflammation, and progressive liver fibrosis. The lack of approved treatments highlights the need to identify new agonists of the farnesoid X receptor (FXR), a key regulator of lipid metabolism and bile acids.
Methods: An integrated AI-assisted drug discovery pipeline was developed, combining a QSAR model based on graph neural networks (GraphConvModel), high-throughput virtual screening, in silico ADMET evaluation, and molecular docking. The model was trained on 3,450 ligands from ChEMBL and PubChem, then applied to screen approximately one million additional molecules from PubChem.
Results: The model achieved high performance (R² = 0.89), reproducing the experimental activity hierarchy. Successive filters (Lipinski, bioavailability, DILI, hERG) led to nine candidate agonists, with molecules M9 (CID: 7190831) and M1 (CID: 8888557) showing the best docking scores (−49.37 and −49.11 kcal/mol). Their stable interactions with residues PHE363, ILE359, TYR358, and TRP451 confirm their agonist potential.
Conclusion: The AI-ADMET-Docking pipeline is a rapid and reliable predictive tool for discovering FXR agonists. These results validate the value of AI in researching innovative treatments for NASH and pave the way for experimental validation of molecule M9 (CID: 7190831).
Keywords: FXR, NASH/MASH, molecular modeling, Artificial Intelligence, Graph Neural Networks (GNN)
Keywords:
FXR, NASH/MASH, molecular modeling, Artificial Intelligence, Graph Neural Networks (GNN)DOI
https://doi.org/10.22270/jddt.v15i11.7449References
1. De A, Panigrahi M, Duseja A, Singh SP. Metabolic-dysfunction associated steatotic liver disease (MASLD). In: Hepatology. Elsevier; 2025:861-888. https://doi.org/10.1016/B978-0-443-26711-6.00031-7
2. Waheed A, Gul MH, Shabbir MUB, et al. FDA approves Resmetirom: groundbreaking treatment for NASH liver scarring in moderate to advanced fibrosis. Annals of Medicine & Surgery. 2025;87(3):1088-1091. https://doi.org/10.1097/MS9.0000000000002770 PMid:40213239 PMCid:PMC11981246
3. Younossi ZM, Golabi P, De Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hepatology. 2019;71(4):793-801. https://doi.org/10.1016/j.jhep.2019.06.021 PMid:31279902
4. Azam MM, Mukhtar S, Haris M, et al. FDA's approval of resmetirom (Rezdiffra): a breakthrough in MASH management. Explor Drug Sci. Published online December 3, 2024:867-874. https://doi.org/10.37349/eds.2024.00078
5. Fahim SA, Attia YM, Messiha A, Nabawy AY, Refaat F, El-Maadawy WH. Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management. Biomedicine & Pharmacotherapy. 2025;193:118731. https://doi.org/10.1016/j.biopha.2025.118731 PMid:41177120
6. Adorini L, Trauner M. FXR agonists in NASH treatment. Journal of Hepatology. 2023;79(5):1317-1331. https://doi.org/10.1016/j.jhep.2023.07.034 PMid:37562746
7. Chen M, Yang X, Lai X, Kang J, Gan H, Gao Y. Structural Investigation for Optimization of Anthranilic Acid Derivatives as Partial FXR Agonists by in Silico Approaches. IJMS. 2016;17(4):536. https://doi.org/10.3390/ijms17040536 PMid:27070594 PMCid:PMC4848992
8. Saha A, Wood E, Omeragic L, et al. Farnesoid X Receptor (FXR) Agonists and Protein Kinase Regulation in NAFLD and NASH: Mechanisms and Therapeutic Potential. Kinases and Phosphatases. 2025;3(3):16. https://doi.org/10.3390/kinasesphosphatases3030016
9. Xiao H, Li P, Li X, et al. Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH. ACS Med Chem Lett. 2017;8(12):1246-1251. https://doi.org/10.1021/acsmedchemlett.7b00318 PMid:29259742 PMCid:PMC5733277
10. Gohda K, Iguchi Y, Masuda A, Fujimori K, Yamashita Y, Teno N. Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism. Bioorganic & Medicinal Chemistry Letters. 2021;41:128026. https://doi.org/10.1016/j.bmcl.2021.128026 PMid:33839252
11. Tully DC, Rucker PV, Chianelli D, et al. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH). J Med Chem. 2017;60(24):9960-9973. https://doi.org/10.1021/acs.jmedchem.7b00907 PMid:29148806
12. Edwards J, LaCerte C, Peyret T, et al. Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage. Clinical Translational Sci. 2016;9(6):328-336. https://doi.org/10.1111/cts.12421 PMid:27743502 PMCid:PMC5351006
13. NASH-Final-Report_Updated_011025.
14. Dufour JF, Anstee QM, Bugianesi E, et al. Current therapies and new developments in NASH. Gut. 2022;71(10):2123-2134. https://doi.org/10.1136/gutjnl-2021-326874 PMid:35710299 PMCid:PMC9484366
15. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers. 2021;25(3):1315-1360. https://doi.org/10.1007/s11030-021-10217-3 PMid:33844136 PMCid:PMC8040371
16. Gangwal A, Ansari A, Ahmad I, et al. Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities. Front Pharmacol. 2024;15:1331062. https://doi.org/10.3389/fphar.2024.1331062 PMid:38384298 PMCid:PMC10879372
17. Bechelli S, Delhommelle J. AI's role in pharmaceuticals: Assisting drug design from protein interactions to drug development. Artificial Intelligence Chemistry. 2024;2(1):100038. https://doi.org/10.1016/j.aichem.2023.100038
18. Jiménez J, Škalič M, Martínez-Rosell G, De Fabritiis G. KDEEP : Protein-Ligand Absolute Binding Affinity Prediction via 3D-Convolutional Neural Networks. J Chem Inf Model. 2018;58(2):287-296. https://doi.org/10.1021/acs.jcim.7b00650 PMid:29309725
19. Kim S, Chen J, Cheng T, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Research. 2021;49(D1):D1388-D1395. https://doi.org/10.1093/nar/gkaa971 PMid:33151290 PMCid:PMC7778930
20. Dash RP, Babu RJ, Srinivas NR. Non-alcoholic Steatohepatitis (NASH) Drug Discovery - Building a Consensus on ADME Screening Tools and Clinical Pharmacology Strategies to Aid Candidate Development. J Pharm Pharm Sci. 2018;21:481-495. https://doi.org/10.18433/jpps30022 PMid:30472977
21. https://colab.research.google.com/. Accessed November 2, 2025. https://colab.research.google.com/
22. visualise. Accessed October 28, 2025. https://www.ebi.ac.uk/chembl/visualise
23. Zdrazil B, Felix E, Hunter F, et al. The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Research. 2024;52(D1):D1180-D1192. https://doi.org/10.1093/nar/gkad1004 PMid:37933841 PMCid:PMC10767899
24. Kearnes S, McCloskey K, Berndl M, Pande V, Riley P. Molecular graph convolutions: moving beyond fingerprints. J Comput Aided Mol Des. 2016;30(8):595-608. https://doi.org/10.1007/s10822-016-9938-8 PMid:27558503 PMCid:PMC5028207
25. Zhang S, Tong H, Xu J, Maciejewski R. Graph convolutional networks: a comprehensive review. Comput Soc Netw. 2019;6(1):11. https://doi.org/10.1186/s40649-019-0069-y PMid:37915858 PMCid:PMC10615927
26. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews. 2012;64:4-17. https://doi.org/10.1016/j.addr.2012.09.019
27. Discovery Studio molecular modeling and simulation program version 2.5, Accelrys, Inc., San Diego, CA, 92121, USA, 2009.
28. Panzitt K, Zollner G, Marschall HU, Wagner M. Recent advances on FXR-targeting therapeutics. Molecular and Cellular Endocrinology. 2022;552:111678. https://doi.org/10.1016/j.mce.2022.111678 PMid:35605722
29. https://admetlab3.scbdd.com/. Accessed November 2, 2025. https://admetlab3.scbdd.com/
30. Mane SA, Baka RL, Hatwar PR, Artificial Intelligence in Pharmaceutical Research, Journal of Drug Delivery and Therapeutics, 2025;15(6):260-267. https://doi.org/10.22270/jddt.v15i6.7234
31. Kydd-Sinclair D, Packer GL, Weymouth-Wilson AC, Watson KA. Structural Basis of Novel Bile Acid-Based Modulators of FXR. Journal of Molecular Biology. 2025;437(21):169383. https://doi.org/10.1016/j.jmb.2025.169383 PMid:40803552
32. Das Mahapatra A, Choubey R, Datta B. Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer. Molecules. 2020;25(23):5488. https://doi.org/10.3390/molecules25235488 PMid:33255197 PMCid:PMC7727688
33. Schmidt J, Rotter M, Weiser T, et al. A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. J Med Chem. 2017;60(18):7703-7724. https://doi.org/10.1021/acs.jmedchem.7b00398 PMid:28845983
34. Laboratoire de Physique Fondamentale et Appliquée (LPFA), University of Abobo Adjamé (now Nangui Abrogoua), Abidjan 02, Côte d'Ivoire, Banquet Okra GM, Brice D, N'Guessan H, Florance Kouassi A, Raymond KN. Conformational analysis and molecular design of anthranilic acid derivatives as partial agonists of the Farnesoid X Receptor (FXR) with favorable predicted pharmacokinetic profiles. SDRP-JCCMM. 2021;5(2):585-600. https://doi.org/10.25177/JCCMM.5.2.RA.10760
35. Wu N, Zhang R, Peng X, Fang L, Chen K, Jestilä JS. Elucidation of protein-ligand interactions by multiple trajectory analysis methods. Phys Chem Chem Phys. 2024;26(8):6903-6915. https://doi.org/10.1039/D3CP03492E PMid:38334015
Published
Abstract Display: 172 
PDF Downloads: 141 PDF Downloads: 28 How to Cite
Issue
Section
Copyright (c) 2025 Guy Müller Banquet Okra , Mona Hermann Charly Yapi , Koffi N’Guessan Placide Gabin Allangba , Koffi Charles Kouman , Yves Kily Hervé Fagnidi , Kré N. Raymond
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.